Morgan Stanley
ABOS icon

Morgan Stanley’s Acumen Pharmaceuticals ABOS Stock Holding History

Morgan Stanley’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$365K Sell
136,763
-7,821
-5% -$19.3K ﹤0.01% 5691
2026
Q1 		$341K Sell
144,584
-22,321
-13% -$56.9K ﹤0.01% 5657
2025
Q4 		$352K Buy
166,905
+17,504
+12% +$34.7K ﹤0.01% 5692
2025
Q3 		$255K Sell
149,401
-4,347
-3% -$6.01K ﹤0.01% 5795
2025
Q2 		$178K Buy
153,748
+1,112
+0.7% +$1.2K ﹤0.01% 5897
2025
Q1 		$168K Sell
152,636
-113,580
-43% -$162K ﹤0.01% 5810
2024
Q4 		$458K Buy
266,216
+27,016
+11% +$65K ﹤0.01% 5454
2024
Q3 		$593K Buy
239,200
+151,391
+172% +$411K ﹤0.01% 5318
2024
Q2 		$212K Buy
87,809
+39,097
+80% +$124K ﹤0.01% 5646
2024
Q1 		$197K Buy
48,712
+25,586
+111% +$96.4K ﹤0.01% 5742
2023
Q4 		$88.8K Buy
23,126
+887
+4% +$2.63K ﹤0.01% 5989
2023
Q3 		$92.3K Buy
22,239
+6,915
+45% +$42.7K ﹤0.01% 5929
2023
Q2 		$73.7K Sell
15,324
-36,184
-70% -$173K ﹤0.01% 6067
2023
Q1 		$209K Buy
51,508
+25,824
+101% +$135K ﹤0.01% 5689
2022
Q4 		$139K Buy
25,684
+6,770
+36% +$45.5K ﹤0.01% 5824
2022
Q3 		$189K Sell
18,914
-5,283
-22% -$30.3K ﹤0.01% 5749
2022
Q2 		$114K Buy
24,197
+10,510
+77% +$39.5K ﹤0.01% 6200
2022
Q1 		$53K Sell
13,687
-6,946
-34% -$37.8K ﹤0.01% 6674
2021
Q4 		$139K Buy
20,633
+20,064
+3,526% +$221K ﹤0.01% 6258
2021
Q3 		$8K Buy
+569
New +$9.47K ﹤0.01% 7384

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Morgan Stanley's ABOS Position: Q2 2026 in Review

Morgan Stanley reduced its Acumen Pharmaceuticals (ABOS) stake by 5.4% in Q2 2026, selling an estimated $19.3K and leaving 136,763 shares worth $365K. The position accounts for ﹤0.01% of the portfolio, ranked #5691.

Morgan Stanley first reported a position in ABOS in Q3 2021 and has held it in 20 quarters since. The position peaked at $593K in Q3 2024. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Morgan Stanley held 136,763 shares of Acumen Pharmaceuticals worth $365K as of Q2 2026.
  • Morgan Stanley sold 7,821 Acumen Pharmaceuticals shares in Q2 2026, an estimated $19.3K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5691 holding.
  • Morgan Stanley first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Morgan Stanley's Acumen Pharmaceuticals position peaked at $593K in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.